CD274 and cancer: Increased TMB (and thus neoantigens) and PD-L1 expression in SFG-mutated cancers could explain why this subtype responds better to ICIs than SFG-wildtype cancers since both TMB and PD-L1 expression are positive predictors of immunotherapy response (Patel and Kurzrock, 2015; Samstein et al., 2019).